← Back to front page
United States · Wires & real time · PR Newswire

Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky

Published by PR Newswire · United States 19 min ago
Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky
PR Newswire

Detailed summary

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential…

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Sellers drove Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares sharply lower on November 9, 2026, after the Company reported third-quarter TRYNGOLZA sales of $9.3 million and cut the drug's full-year sales guidance to roughly $50 million from $100-$110 million. If you bought IONS and are now holding losses, you may have legal rights, and Levi & Korsinsky is investigating. IONS shareholders who lost money are encouraged to submit their loss details for a free review . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Ionis beat consensus estimates on both revenue and earnings per share. Shares fell anyway. Third-quarter commercial revenue rose 18% year over year, which the Company attributed primarily to DAWNZERA product sales. TRYNGOLZA sales, however, were only $9.3 million, compared with $31.8 million in the third quarter of 2025.

TRYNGOLZA recorded approximately $32 million in first-half 2026 sales. To reach the prior $100-$110 million target, the drug needed roughly $68-$78 million over the final six months. The third quarter delivered $9.3 million. The revised full-year figure of roughly $50 million sits $50-$60 million below the original range.

If you are holding IONS losses after the November 9 sell-off, see if you may be eligible to recover your IONS losses or call (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Q: How much did IONS stock drop? A: IONS shares fell roughly $7.27, or about 18.44% to open at approximately $32.15 on November 9, 2026, after the Company disclosed that it had cut its…

Q: Which…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading